AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Saved in:
| Title: | AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. |
|---|---|
| Authors: | Ren Z; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China., Huang Y; Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China., Guo Y; Liver Tumor Center, Nanfang Hospital Southern Medical University, Guangzhou, China., Hou MM; Division of Hematology and Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan., Wang W; Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, China., Kuang M; The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Hao C; Beijing Cancer Hospital, Beijing, China., Wang W; West China Hospital Sichuan University, Chengdu, Sichuan, China., Zhang Y; Gastroenterology Department, Harbin Medical University Cancer Hospital, Harbin, China., Song T; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Dai C; Shengjing Hospital of China Medical University, Shenyang, China., Kuo HT; Chi Mei Medical Center, Tainan, Taiwan.; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan., Bao Z; Solid Tumors, BeOne Medicines, Ltd, Shanghai, China., Zuo Y; Clinical Development, BeOne Medicines, Ltd, Shanghai, China., Wang L; Statistics, BeOne Medicines, Ltd, Beijing, China., Zhu F; Clinical Biomarkers, BeOne Medicines, Ltd, Shanghai, China., Fan J; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. fan.jia@zs-hospital.sh.cn.; Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. fan.jia@zs-hospital.sh.cn. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Apr 28; Vol. 75 (5). Date of Electronic Publication: 2026 Apr 28. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-026-04399-8 |
